ArticleFrontiers in toxicology2026
Hyperbaric oxygen therapy for ischemic encephalopathy following occupational exposure to high-concentration toxic gases: two Case Reports.
Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperbaric oxygen therapy (HBOT) is effective in managing ischemic encephalopathy of various etiologies, particularly following acute intoxication with specific gases. Considering the limited clinical evidence regarding HBOT for hypoxic encephalopathy induced by occupational exposure to toxic gases, investigating this therapeutic approach is clinically important. We report two cases of occupational poisoning due to inhalation of high-concentration toxic gases, both presenting with loss of consciousness and significant neurological deficits. Case 1 involved biogas inhalation, and case 2 involved hydrogen sulfide exposure. Following HBOT, both patients demonstrated significant neurological recovery compared to their pre-treatment status. These findings indicate that HBOT reduces neurological impairment and is associated with favorable clinical outcomes. Therefore, HBOT should be considered for ischemic encephalopathy secondary to high-risk occupational gas exposure. This approach holds potential clinical significance for preventing severe neurological sequelae in workers at risk and provides clinicians with evidence-based guidance for managing toxic gas-induced neurological injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.